Marksans Pharma UK subsidiary gains MHRA approval for Exemestane tablet

Marksans Pharma Limited's wholly owned UK subsidiary, Relonchem Limited, has received Marketing Authorization from the UK MHRA for its Exemestane 25mg film-coated tablets. This approval, announced on November 5, 2025, marks a notable regulatory milestone for the company's product portfolio.

Marksans Pharma, headquartered in Mumbai, India, researches, manufactures, and markets generic pharmaceutical formulations globally. The company's manufacturing facilities in India, USA, and UK hold approvals from leading regulatory agencies including the USFDA, UKMHRA, and Australian TGA.

The company's diverse product portfolio spans major therapeutic segments such as CVS, CNS, anti-diabetic, pain management, gastroenterological, and anti-allergies, with these products marketed internationally.